Healthcare
Diagnostics
from 575 today
We revise our forecasts lower as we take a cautious stance on incremental margins from Rajasthan project. We retain BUY with a Target Price of Rs. 798, based on 23x FY28E EPS.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
